Clinical trial

Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for Hepatocellular Carcinoma (HCC)

Name

STU-2019-1758

Description

This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment and obtain blood samples pre and post TACE for biomarker identification using bead based X-aptamer library. No intervention is planned.

Trial arms

Trial start

2022-11-04

Estimated PCD

2024-12-01

Trial end

2025-12-01

Status

Recruiting

Treatment

Lipiodol

Lipiodol TACE procedure

Arms:

HCC for Lipiodol TACE, denovo ablation, or Y90 radioembolization

Size

Primary endpoint

Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for overall survival in hepatocellular carcinoma patients

2 years

Eligibility criteria

Inclusion Criteria: 1. Ability to understand and the willingness to sign a written informed consent. 2. Male or female aged 18-70years. 3. Diagnosed with primary or metastatic liver cancer. 4. Scheduled to undergo Lipoidal TACE, denovo ablation, or Yttrium-90 (Y90) radioembolization as part of standard of care. Exclusion Criteria: Subjects who have received chemotherapy, radiation or surgery for HCC.

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Pre and Post-TACE blood samples'}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}

Updated at

2023-12-12

1 organization

1 product

1 indication

Organization

University of Texas Southwestern Medical Center

Product

Lipiodol

Indication

Hepatocellular Carcinoma